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ABSTRACT 
 
Background:   
Chronic kidney disease is a progressive disorder with involvement of various 
organs.  CKD MBD is a systemic disorder of mineral and bone metabolism which is 
manifested by either one or a combination of abnormalities of calcium, 
phosphorous, PTH or Vit D metabolism. This results in changes in bone 
mineralisation or growth and other complications like vascular or other soft tissue 
calcification. The hormone fibroblast growth factor (FGF23) is derived from bone 
and its important function in controlling phosphorous levels.  Elevation of serum 
levels of FGF23 is one of the possible causes of left ventricular hypertrophy and 
diastolic dysfunction. This leads to various morbidities and early mortalities in these 
patients. This study was done to observe calcium, phosphorous, iPTH and especially 
FGF23 and to note any role of FGF23 in causing cardiac involvement in these 
patients. 
Methods:  
Ethical committee clearance was obtained. After taking informed consent, 
50 patients were enrolled in the study between September 2017 and February 
2018.All subjects were in the group 20-70 years. Cardiac systolic function was 
assessed by echo. Mineral bone disorder was assessed by Serum FGF23, calcium, 
phosphorous, parathyroid hormone, in all patient. The data was analysed by SPSS 
VERSION 20.0 
 
 
Results:  
In our study found that among 50 study participants 88 percent patients had 
hyperphosphataemia, 64 percent had hypocalcemia, 46 percent had elevated 
parathormone and 74 percent had elevated FGF23. All the patients had biochemical 
evidence of mineral bone disorder. In them 20 percent had left ventricular 
hypertrophy, and left ventricular diastolic dysfunction. Reduced ejection was noted 
in 10 percent of patients. Positive correlation was noted with level of phosphorous 
and FGF23.The left ventricular hypertrophy was also noted in those with elevated 
FGF23 and it was statistically significant.  Statistically there was no correlation with 
the level of calcium, ipth or reduced ejection fraction in relation to FGF23.  
 
Conclusion:  
CKD MBD is common in patients with ckd especially stage 5.  They are also 
prone for cardiovascular manifestation. FGF23 levels were high in those with 
elevated phosphorous, left ventricular hypertrophy and left ventricular dysfunction.  
Levels of Calcium, ipth and ejection fraction did not correlate with FGF23. Larger 
population in the study would have helped in actual identification of these patients 
and also helped in the knowing the predominant role of FGF23. 
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